Aarti Pharmalabs Ltd — earnings calls

Aarti Pharmalabs reported Q4 FY2026 standalone revenue of Rs.580 Crores, up 9% year-on-year, while full year FY2026 revenue was Rs.1798 Crores against Rs.1771 Crores in FY2025. EBITDA and profit after tax declined both for the quarter and the full year compared to the previous year, with management citing a net foreign exchange loss and cost pressures from the West Asia conflict. Management discussed segment performance across Xanthine derivatives, API/Intermediates and CDMO/CMO, and outlined capex plans and capacity expansions at Tarapur and Atali for the coming year.